BD, one of the largest syringe manufactures in the U.S., has announced that they are changing the scale markings of their 60 mL syringe to a 50 mL syringe. While the product is not receiving changes to the device form, fit, function or composition, the gradation markers will no longer be extended beyond 50 mL.

These syringes are most commonly used in the primary immunodeficiency disease (PI) community by those who use subcutaneous immunoglobulin replacement therapy (SCIG). These syringes that are standard in the use for SCIG could potentially cause some confusion and/or misdosing for individuals.

These newly labeled BD® 50 mL syringes have already been released and will be first used between October through December 2019 as the supply of the 60 mL syringe runs out. As this change takes place, it’s unlikely to significantly alter the user experience or how it is handled by insurance, but we encourage all those who use this product to be aware, be ready and speak to your care team.

For more information, read the statement from BD.